I-Mab (IMAB) said Thursday it has agreed to buy Bridge Health Biotech for an upfront payment of $1.8 million, plus $1.2 million in non-contingent payments through 2027.
Bridge Health Biotech shareholders may also be entitled to future milestone payments of up to about $3.9 million, I-Mab said.
The deal, which will likely be completed in Q3, gives I-Mab upstream rights to the CLDN18.2 parental antibody for use in bispecific and multi-specific applications, the company added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。